Slide 1: Q&A session and material Forward looking statements
Q&A session and material Forward looking statements • IMPORTANT: The following applies to this document, the oral presentation of the information in this document by • Questions can be raised via the Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any question-and-ans
Slide 2: Company performance and test performance
Company performance and test performance Q2 2024 Report August 5 2024 2
Slide 3: Agenda
Agenda 01 Next-generation test performance 02 Lab and product platform 03 Clinical roadmap 04 Q2 financials and cash position 05 Rights issue 06 Questions and answers 3
Slide 4: We have completed development of our next-generation test and substantially increased its accuracy
We have completed development of our next-generation test and substantially increased its accuracy 98% 85% Specificity Sensitivity 20% points more sensitive than CA19-9 4
Slide 5: Significant increase in test performance
Significant increase in test performance An expansion of the number of Additional patient samples with biomarkers included in the test richer clinical data Different coefficients in the equation that combines biomarker levels More sophisticated statistical modeling, especially for CA19-9 +10% points
Slide 6: We will present next-generation test results at key scientific meetings in 2024
We will present next-generation test results at key scientific meetings in 2024 PancreasFest PancreasFest 2024 AACR Special Conference in Cancer Research: Collaborative Group of the Americas on July 25 – 26, 2024 Advances in Pancreatic Cancer Research Inherited Gastrointestinal Cancer Cincinnati, Oh
Slide 7: Lean, efficient new lab in North Carolina will fuel success and lower costs
Lean, efficient new lab in North Carolina will fuel success and lower costs • Lab was fully operational 6 weeks after move-in • Lab is fully staffed, led by Lisa Ford, PhD, HCLD • All equipment installed and validated • Processes developed and documented • Assays for the next-generation test have be
Slide 8: Lean, efficient new lab in North Carolina will fuel success and lower costs
Lean, efficient new lab in North Carolina will fuel success and lower costs ELISA platform Most tests can be Our labor and Discontinuing the measures proteins completed the same materials cost per IMMray platform has more accurately than day they are received test will be much drastically reduced IM
Slide 9: Rapid and cost-efficient development of our next-generation test
Rapid and cost-efficient development of our next-generation test Research Phase Development Phase Q4’22 Q1’23 Q2’23 Q3’23 Q4’23 Q1’24 Q2’24 Q3’24 Q4’24 Clinical Proposal Discovery Definition Analytical Validation Validation Review & assess Successfully found over a dozen proteins in Finalize develop
Slide 10: Analytical validation will confirm performance of individual protein assays
Analytical validation will confirm performance of individual protein assays • Series of more than 25 experiments • Measures numerous assay parameters, including precision, stability, ruggedness, and more • Conducted under guidelines from US FDA, CLIA, CLSI • Expected completion: September 2024 10
Slide 11: Clinical validation will confirm the performance and accuracy of the next-generation test
Clinical validation will confirm the performance and accuracy of the next-generation test • Objective: Confirm the accuracy and performance of the next-generation test shown in the model- development study • Sample size: Over 1,000 pancreatic cancer and control samples • Conducted in partnership wit
Slide 12: Committed to bringing the next-generation test to market in 2025
Committed to bringing the next-generation test to market in 2025 Setting the stage for commercialization with a partner • Cost-effective approach to commercialization utilizing the partner’s existing sales team and commercial resources • Leverage Immunovia’s KOL relationships to drive adoption • Inv
Slide 13: Next-generation test to be included in NIH funded SEK 48 million study of pancreatic cysts
Next-generation test to be included in NIH funded SEK 48 million study of pancreatic cysts 3 complementary studies to evaluate biomarker tests in patients with cystic tumors of the pancreas Lead Investigator • Study 1: Define the accuracy of blood-based biomarkers in a Diane M. Simeone, MD retrospec
Slide 14: Q2 Financial Results - Summary
Q2 Financial Results - Summary • Cash balance 37 MSEK • Cash burn expected to stay around 8-9 MSEK per Reduced HC cotmonth in line with previous guidance • Cash together with secured proceeds from the rights issue will take the Company through 2024 14
Slide 15: Staffing and operating expense reductions are significantly reducing our cash burn
Staffing and operating expense reductions are significantly reducing our cash burn – financially delivering on plan OPEX • Substantially reduced vs Q2 2023 (approx. 20 MSEK) • Flat vs Q1 2024 – delivering on plan • HC cost dramatically decreased – down 74% vs Q2 2023 Cash burn – in line with expecta
Slide 16: Rights issue approved by shareholders will fund analytical and clinical validation
Rights issue approved by shareholders will fund analytical and clinical validation • Issue size: 70 MSEK • Secured level 50% • 1 unit consists of 2 shares, 2 TO2 warrants, 1 TO3 warrant • Subscription period 16 – 30 August • Terms to be announced 6 August 16
Slide 17: Learn more about Immunovia, our test and the rights issue
Learn more about Immunovia, our test and the rights issue at rightsissue.immunovia.com 17
Slide 18: We have turned the corner and are driving toward commercial launch
We have turned the corner and are driving toward commercial launch with our high- performance test. Investment in the rights issue will fuel critical next steps for US commercialization and reimbursement rightsissue.immunovia.com 18
Slide 19: Q&A
Q&A 19